Tomas Forslund

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023;32(11):1223-1232
Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries
Komen JJ; Hunt NB; Pottegard A; Hjemdahl P; Wettermark B; Olesen M; Bennie M; Mueller T; Carragher R; Karlstad O; Kjerpeseth LJ; Klungel OH; Forslund T
Article: EUROPEAN HEART JOURNAL. 2022;43(37):3528-3538
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
Komen JJ; Pottegard A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hallas J; Olesen M; Bennie M; Mueller T; Carragher R; Karlstad O; Kjerpeseth LJ; Klungel OH
Article: HEART. 2022;108(8):613-618
Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
Komen J; Pottegard A; Hjemdahl P; Mantel-Teeuwisse AK; Wettermark B; Hellfritzsch M; Hallas J; Herings R; Smits L; Forslund T; Klungel O
Article: EUROPACE. 2021;23(11):1722-1730
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
Komen JJ; Pottegard A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hellfritzsch M; Hallas J; Olesen M; Bennie M; Mueller T; Voss A; Schink T; Haug U; Kollhorst B; Karlstad O; Kjerpeseth LJ; Klungel OH
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2021;10(16):e021716
Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation
Forslund T; Braunschweig F; Holzmann MJ; Siddiqui AJ
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021;30(7):934-951
Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study
Komen JJ; Belitser SV; Wyss R; Schneeweiss S; Taams AC; Pajouheshnia R; Forslund T; Klungel OH
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(F11):f72-f80
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
Komen JJ; Heerdink ER; Klungel OH; Mantel-Teeuwisse AK; Forslund T; Wettermark B; Hjemdahl P
Article: FAMILY PRACTICE. 2021;38(2):132-140
Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study
Forslund T; Carlsson AC; Ljunggren G; Arnlov J; Wachtler C
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(1):3-10
Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality
Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Article: BMC PSYCHIATRY. 2020;20(1):328
Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study
Forslund T; Kosidou K; Wicks S; Dalman C
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;107(1):287-294
Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding
Komen JJ; Hjemdahl P; Mantel-Teeuwisse AK; Klungel OH; Wettermark B; Forslund T
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2019;48(4):668-673
Venous thromboembolism 2011-2018 in Stockholm: a demographic study
Wandell P; Forslund T; Danin Mankowitz H; Ugarph-Morawski A; Eliasson S; Braunschwieg F; Holmstrom M
Article: STROKE. 2018;49(9):2122-2128
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience
Forslund T; Komen JJ; Andersen M; Wettermark B; von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
Article: EUROPACE. 2018;20(3):420-428
Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
Forslund T; Wettermark B; Andersen M; Hjemdahl P
Article: AMERICAN JOURNAL OF CARDIOLOGY. 2017;120(8):1302-1308
Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants
Loikas D; Forslund T; Wettermark B; Schenck-Gustafsson K; Hjemdahl P; von Euler M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2017;73(10):1315-1322
Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
Komen J; Forslund T; Hjemdahl P; Wettermark B
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2017;83(3):642-652
Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis
Komen J; Forslund T; Hjemdahl P; Andersen M; Wettermark B
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;72(3):329-338
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
Forslund T; Wettermark B; Hjemdahl P
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(12):1477-1485
Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA₂DS₂VASc scores: experience from the Stockholm region
Forslund T; Wettermark B; Wandell P; von Euler M; Hasselstrom J; Hjemdahl P
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2013;170(2):208-214
Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system
Forslund T; Wettermark B; Wandell P; von Euler M; Hasselstrom J; Hjemdahl P
Article: JOURNAL OF OBESITY. 2011;2011:459263-7
Usage, Risk, and Benefit of Weight-Loss Drugs in Primary Care
Forslund T; Raaschou P; Hjemdahl P; Krakau I; Wettermark B
Article: LAKARTIDNINGEN. 2010;107(13-14):910-913
[Anti-obesity agents do not seem to have any beneficial effects. Health centers prescribe preparations haphazardly, according to a medical records study].
Forslund T; Wettermark B; Raaschou P; Hjemdahl P; Krakau I
Visa fler

Alla övriga publikationer

Letter: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(3):e31
Themultiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? Response
Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Review: LAKARTIDNINGEN. 2018;115:FAH6
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Hjemdahl P; Braunschweig F; Holmström M; Johnsson H; von Euler M; Wallén H; Forslund T
Thesis / dissertation: 2017
Antithrombotic treatment of atrial fibrillation before and after the introduction of non-vitamin K antagonist oral anticoagulants (NOAC) in the Stockholm health care region
Forslund, Tomas
Review: LAKARTIDNINGEN. 2015;112:CZYS
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Forslund T; von Euler M; Johnsson H; Holmström M; Wettermark B; Hjemdahl P

Anställningar

Anknuten till Forskning, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2024-2027

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2017
Läkarexamen, Karolinska Institutet, 2002

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI